{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:47:47Z","timestamp":1794887267398,"version":"4.9.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019533","name":"Moderna Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019533","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>mRNA-1345 is a respiratory syncytial virus (RSV) vaccine approved for prevention of RSV-associated lower respiratory tract disease in individuals \u2265 60 years. Durability of efficacy is being evaluated in clinical trials. Data on revaccination in adults are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This open-label, phase 3 trial evaluated revaccination with 50\u2005\u00b5g mRNA-1345 administered 12 months after primary vaccination in participants aged \u226550 years. The primary objectives were the immunogenicity (RSV-A and RSV-B neutralizing antibody [nAb] responses), tolerability, and safety of revaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 543 participants were revaccinated. Most adverse reactions were mild\/moderate (median duration, 2 days), with no new safety concerns identified. Coprimary immunogenicity endpoints met prespecified noninferiority criteria based on Day 29 geometric mean titer ratios (GMRs; revaccination vs primary vaccination). At Day 29, nAb GMRs (95% confidence interval [CI]) were 1.08 (1.0\u20131.17) for RSV-A and 0.91 (.84\u2013.98) for RSV-B. Seroresponse rates (\u22654-fold rise from baseline; 95% CI) at Day 29 were 77.5% (73.7\u201381.0) for RSV-A and 47.5% (43.2\u201351.9) for RSV-B, with a \u22652-fold rise in titers observed in 91.6% (88.9\u201393.8) and 69.8% (65.7\u201373.8) of participants, respectively. Following primary vaccination, RSV nAb titers increased by Day 29 and gradually declined over 12 months, yet remained above baseline levels. Revaccination at 12 months increased nAb titers, similar to the response observed after the primary dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Revaccination of adults \u2265 50 years with mRNA-1345 was well tolerated, with a safety profile consistent with the primary dose. Respiratory syncytial virus nAb at Day 29 was noninferior to those after a primary mRNA-1345 dose, with antibody response persisting for 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov: NCT05330975.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf515","type":"journal-article","created":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:52:56Z","timestamp":1758369176000},"page":"e855-e862","source":"Crossref","is-referenced-by-count":12,"title":["Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against Respiratory Syncytial Virus, Administered 12 Months Following a Primary Dose in Adults Aged \u226550 Years"],"prefix":"10.1093","volume":"82","author":[{"given":"Jaya","family":"Goswami","sequence":"first","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1601-1461","authenticated-orcid":false,"given":"Jose F","family":"Cardona","sequence":"additional","affiliation":[{"name":"Indago Research and Health Center , Hialeah, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Caso","sequence":"additional","affiliation":[{"name":"Suncoast Research Associates LLC , Miami, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise C","family":"Hsu","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alana K","family":"Simorellis","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Wilson","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Dhar","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Wang","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avi","family":"Collins","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius","family":"Righi","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Lan","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiejun","family":"Du","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia K","family":"Stoszek","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine A","family":"Shaw","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Reuter","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4855-514X","authenticated-orcid":false,"given":"Eleanor","family":"Wilson","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rituparna","family":"Das","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"2026043013132948300_ciaf515-B1","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1128\/CMR.13.3.371","article-title":"Respiratory syncytial virus infection in adults","volume":"13","author":"Falsey","year":"2000","journal-title":"Clin Microbiol Rev"},{"key":"2026043013132948300_ciaf515-B2","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa043951","article-title":"Respiratory syncytial virus infection in elderly and high-risk adults","volume":"352","author":"Falsey","year":"2005","journal-title":"N Engl J Med"},{"key":"2026043013132948300_ciaf515-B3","doi-asserted-by":"crossref","first-page":"S577","DOI":"10.1093\/infdis\/jiz059","article-title":"Global disease burden estimates of respiratory syncytial virus-associated acute respiratory infection in older adults in 2015: a systematic review and meta-analysis","volume":"222","author":"Shi","year":"2020","journal-title":"J Infect Dis"},{"key":"2026043013132948300_ciaf515-B4","doi-asserted-by":"crossref","first-page":"e13031","DOI":"10.1111\/irv.13031","article-title":"Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: a systematic literature review and meta-analysis","volume":"17","author":"Savic","year":"2023","journal-title":"Influenza Other Respir Viruses"},{"key":"2026043013132948300_ciaf515-B5","doi-asserted-by":"crossref","first-page":"696","DOI":"10.15585\/mmwr.mm7332e1","article-title":"Use of respiratory syncytial virus vaccines in adults aged \u226560 years: updated recommendations of the advisory committee on immunization practices\u2014United States, 2024","volume":"73","author":"Britton","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026043013132948300_ciaf515-B6","author":"Das"},{"key":"2026043013132948300_ciaf515-B7"},{"key":"2026043013132948300_ciaf515-B8","author":"Britton"},{"key":"2026043013132948300_ciaf515-B9","author":"Food and Drug Administration"},{"key":"2026043013132948300_ciaf515-B10","author":"Moderna"},{"key":"2026043013132948300_ciaf515-B11"},{"key":"2026043013132948300_ciaf515-B12","author":"Moderna"},{"key":"2026043013132948300_ciaf515-B13","doi-asserted-by":"crossref","first-page":"e996","DOI":"10.1093\/infdis\/jiae316","article-title":"Humoral immunogenicity of mRNA-1345 RSV vaccine in older adults","volume":"230","author":"Goswami","year":"2024","journal-title":"J Infect Dis"},{"key":"2026043013132948300_ciaf515-B14","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults","volume":"389","author":"Wilson","year":"2023","journal-title":"N Engl J Med"},{"key":"2026043013132948300_ciaf515-B15","doi-asserted-by":"crossref","first-page":"e647","DOI":"10.1093\/infdis\/jiae081","article-title":"Safety and immunogenicity of an mRNA-based RSV vaccine including a 12-month booster in a phase I clinical trial in healthy older adults","volume":"230","author":"Shaw","year":"2024","journal-title":"J Infect Dis"},{"key":"2026043013132948300_ciaf515-B16","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1473-3099(24)00589-9","article-title":"Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial","volume":"25","author":"Goswami","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2026043013132948300_ciaf515-B17","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s40266-024-01118-9","article-title":"Respiratory syncytial virus infection in older adults: an update","volume":"41","author":"Alfano","year":"2024","journal-title":"Drugs Aging"},{"key":"2026043013132948300_ciaf515-B18","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1473-3099(17)30396-1","article-title":"Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015","volume":"17","author":"GBD 2015 LRI Collaborators","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2026043013132948300_ciaf515-B19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/infdis\/163.4.693","article-title":"Immunity to and frequency of reinfection with respiratory syncytial virus","volume":"163","author":"Hall","year":"1991","journal-title":"J Infect Dis"},{"key":"2026043013132948300_ciaf515-B20","author":"Pfizer"},{"key":"2026043013132948300_ciaf515-B21","author":"GlaxoSmithKline"},{"key":"2026043013132948300_ciaf515-B22","author":"Centers for Disease Control and Prevention"},{"key":"2026043013132948300_ciaf515-B23","author":"Pfizer"},{"key":"2026043013132948300_ciaf515-B24","author":"Centers for Disease Control and Prevention"},{"key":"2026043013132948300_ciaf515-B25","author":"Schwarz"},{"key":"2026043013132948300_ciaf515-B26","doi-asserted-by":"crossref","first-page":"7641","DOI":"10.1016\/j.vaccine.2018.10.087","article-title":"Establishment of the first WHO international standard for antiserum to respiratory syncytial virus: report of an international collaborative study","volume":"36","author":"McDonald","year":"2018","journal-title":"Vaccine"},{"key":"2026043013132948300_ciaf515-B27","doi-asserted-by":"crossref","first-page":"eadp5218","DOI":"10.1126\/sciimmunol.adp5218","article-title":"Anti-immune complex antibodies are elicited during repeated immunization with HIV Env immunogens","volume":"10","author":"Brown","year":"2025","journal-title":"Sci Immunol"},{"key":"2026043013132948300_ciaf515-B28","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3390\/v16060973","article-title":"The immune system-a double-edged sword for adenovirus-based therapies","volume":"16","author":"Wallace","year":"2024","journal-title":"Viruses"},{"key":"2026043013132948300_ciaf515-B29","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"2026043013132948300_ciaf515-B30","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1038\/s41564-024-01860-1","article-title":"A foldon-free prefusion F trimer vaccine for respiratory syncytial virus to reduce off-target immune responses","volume":"9","author":"Bakkers","year":"2024","journal-title":"Nat Microbiol"},{"key":"2026043013132948300_ciaf515-B31","author":"Warter"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf515\/64356743\/ciaf515.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/4\/e855\/64356743\/ciaf515.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/4\/e855\/64356743\/ciaf515.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:13:34Z","timestamp":1777569214000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/4\/e855\/8262625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,9,24]]},"published-print":{"date-parts":[[2026,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf515","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,15]]},"published":{"date-parts":[[2025,9,24]]}}}